Pieris Pharmaceuticals Inc (NAS:PIRS)
$ 10.3 0.1 (0.98%) Market Cap: 13.60 Mil Enterprise Value: -12.90 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 46/100

Pieris Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 04:00PM GMT
Release Date Price: $413.6
Emma Nealon
Cantor Fitzgerald - Analyst

Good afternoon, everyone, and thank you for joining us on day four of the virtual Cantor healthcare conference. My name is Emma Nealon, and I'm one of the small/mid-cap biotech analysts here at Cantor. And it's my pleasure to introduce our next presenting company, Pieris Pharmaceuticals. Joining us today from Pieris is CEO Stephen Yoder. Steve, I'll turn it over to you to take us through the story.

Stephen Yoder
Pieris Pharmaceuticals, Inc. - CEO

Thank you very much, Emma, and thanks as well to Cantor for the invitation and the opportunity to present Pieris Pharmaceuticals to you all today. For those of you who don't know much about Pieris, or anything about Pieris, you can think of us as a large molecule R&D company, and I'm happy to share the story with you today. We've had a great first half of the year and looking at a lot of opportunities over the next couple of quarters. As I share the story with you today, I will be making forward-looking statements, so of course, you can consult our disclaimer.

And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot